Pani Apostolidis
About Pani Apostolidis
Pani Apostolidis is the Director of External Tech Transfer at Kite Pharma, where he has worked since 2020. He has a strong background in manufacturing sciences and technology, with extensive experience in upstream process development and regulatory submissions.
Current Role at Kite Pharma
Pani Apostolidis serves as the Director of External Tech Transfer for Global MSAT at Kite Pharma. This position has been held since 2020, and it is based in Santa Monica, California. In this role, Apostolidis focuses on external technology transfer processes, contributing to the company's mission in the biopharmaceutical sector.
Previous Experience at Kite Pharma
Apostolidis has held multiple positions at Kite Pharma. He worked as the Director of Process Development in the Lifecycle Management Team for eight months in 2020. Prior to this, he was the Associate Director of Process Development in the same team for one year from 2019 to 2020. Additionally, he served as a Senior Engineer in Process Development for six months in 2018, all based in Santa Monica, California.
Educational Background
Apostolidis earned a PhD in Chemical and Biological Engineering from Northwestern University, where he studied from 2004 to 2010. He also holds a Diploma in Chemical Engineering from Aristotle University of Thessaloniki, which he completed from 1999 to 2004. His education has provided a strong foundation for his career in the biopharmaceutical industry.
Research and Academic Experience
Apostolidis has extensive academic experience, including a role as a Visiting Scholar in the Papoutsakis lab at the University of Delaware from 2007 to 2010. He also worked as a Postdoctoral Researcher in the Woulfe lab at the University of Delaware for six months in 2010-2011. His research background includes significant work as a Research Assistant at Northwestern University from 2004 to 2010.
Expertise in Manufacturing Sciences and Technology
Apostolidis possesses strong expertise in Manufacturing Sciences and Technology (MS&T), particularly in upstream cell culture processes. His experience includes roles at Bristol-Myers Squibb, where he worked as a Scientist and Engineer II in MS&T from 2014 to 2018. He has a proven track record in continuous improvement projects, CMC regulatory submissions, and manufacturing investigations.